Exero Medical, a US and Israel based company focused on early detection of post-operative complications using tissue healing data, has secured up to $12.7M in funding to complete its FDA pivotal trial and launch its breakthrough-designated xBar system in the United States. The round includes $10M in upfront funding and additional milestone-based warrants, as well as $2.7M in non-dilutive grants.

The study, which includes eleven sites in the US and Israel, is enrolling patients undergoing colorectal resection surgery to validate the safety and accuracy of Exero’s xBar system for early detection of major, life-threatening complications such as an anastomotic leaks.

There has been a robust start of Exero Medical’s new, international, pivotal, multi-center study of its xBar system.

JUNE 7, 2023 — AUSTIN, TEXAS / OR YEHUDA, ISRAEL — Unorthodox Ventures, the investment firm led by contrarian entrepreneur and Big Ass Fans Founder Carey Smith, today announced it has provided bridge financing toward a series A round for medical device startup Exero Medical. The clinical stage Israeli medical device company has developed implantable technology that monitors healing after surgery, reducing life-threatening complications.

Initial data from 50 patients participating in a multi-center, clinical study demonstrates that Exero Medical’s xBar has the ability to reliably detect anastomotic leaks following gastrointestinal surgery at least three days earlier than the current standard of care – a potentially life-saving early alert.

Source: Journal of Surgical Research Date: July 12, 2022 Original Article: External Link The findings are the basis of a multi-center clinical trial currently ongoing at Rabin Medical Center, Sheba Medical Center, Shamir Medical Center and Kaplan Medical Center Or Yehuda, Israel, July 12, 2022 — A pre-clinical study using Exero Medical’s post-operative tissue healing […]

Diagnosis is crucial to providing efficacious healthcare. Let’s have a look at the history.

We are interviewing leaders of tech companies who are creating or have created a tech product that is helping to make a positive change in people’s lives or the environment.

Exero Medical has enrolled the first patient in its multi-center safety and feasibility study of the company’s flagship product, the xBar tissue monitoring and diagnostic system.

Curiosity and Technology Started a Company and Solved a Medical Problem with CEO Erez Shor | Ep 477

Learn about what’s new at the MEDX Xelerator LP Xelerator, including the current $1M #InterventionalOncology #MedTech Challenge.

The company’s Smart Drain technology for early detection of anastomotic leaks awarded US and Chinese patent for use of resorbable and other structures in monitoring of healing and inflammation following GI surgery.

today announced that an abstract describing its first in human data was selected for presentation at the ‘The Next Big Thing’ session of the SAGES 2021 annual meeting.

Telemedicine gains traction during the COVID-19 pandemic (Hebrew)

Exero Medical, developer of a wireless system for early detection of anastomotic leaks (AL) following gastrointestinal (GI) surgery, today announced the appointment of Dr. Deborah Nagle, Chief of the Colon and Rectal Division of Renaissance School of Medicine at Stony Brook University, to its scientific advisory board.

The FDA Breakthrough Designation status stands reserved for medical devices who have the potential to provide more effective treatment or diagnosis of potentially life-threating conditions or disease.

Exero Medical has developed a life-saving device to help surgeons detect anastomotic leaks in patients early after GI surgery. The sensor has a minimal impact on the surgical procedure, it adds negligible risk and minimal patient discomfort.

Detection can be achieved by using a biosensing system which is implanted near the surgical site. These implantable sensors are able to detect physiological conditions of the tissue.